These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 26896194)

  • 61. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study.
    Terrault NA; Stravitz RT; Lok AS; Everson GT; Brown RS; Kulik LM; Olthoff KM; Saab S; Adeyi O; Argo CK; Everhart JE; Rodrigo del R;
    Hepatology; 2014 Apr; 59(4):1311-9. PubMed ID: 24677192
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation.
    O'Leary JG; Kaneku H; Banuelos N; Jennings LW; Klintmalm GB; Terasaki PI
    Am J Transplant; 2015 Apr; 15(4):1003-13. PubMed ID: 25772599
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.
    Farrero Torres M; Pando MJ; Luo C; Luikart H; Valantine H; Khush K
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28940521
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study.
    Freise CE; Gillespie BW; Koffron AJ; Lok AS; Pruett TL; Emond JC; Fair JH; Fisher RA; Olthoff KM; Trotter JF; Ghobrial RM; Everhart JE;
    Am J Transplant; 2008 Dec; 8(12):2569-79. PubMed ID: 18976306
    [TBL] [Abstract][Full Text] [Related]  

  • 66. De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation - a retrospective study.
    Kovandova B; Slavcev A; Honsova E; Erhartova D; Skibova J; Viklicky O; Trunecka P
    Transpl Int; 2020 Dec; 33(12):1799-1806. PubMed ID: 33020979
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance.
    Waki K; Sugawara Y; Mizuta K; Fujita H; Kadowaki T; Kokudo N
    Clin Transpl; 2011; ():223-35. PubMed ID: 22755416
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation.
    Rao S; Ghanta M; Lee IJ; Gillespie A; Parekh HK; Geier SS; Zeng X; Karachristos A; Lau KN; Karhadkar S; Di Carlo A; Sifontis NM; Constantinescu S
    Clin Transpl; 2014; ():143-51. PubMed ID: 26281139
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The impact of preformed donor-specific antibodies in living donor liver transplantation according to graft volume.
    Goto R; Ito M; Kawamura N; Watanabe M; Ganchiku Y; Kamiyama T; Shimamura T; Taketomi A
    Immun Inflamm Dis; 2022 Mar; 10(3):e586. PubMed ID: 35064772
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
    Clerkin KJ; Farr MA; Restaino SW; Zorn E; Latif F; Vasilescu ER; Marboe CC; Colombo PC; Mancini DM
    J Heart Lung Transplant; 2017 May; 36(5):540-545. PubMed ID: 27916323
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Donor-specific antibodies detected by single antigen beads alone can help risk stratify patients undergoing retransplantation across a repeat HLA mismatch.
    Lucisano G; Thiruvengadam S; Hassan S; Gueret-Wardle A; Brookes P; Santos-Nunez E; Willicombe M
    Am J Transplant; 2020 Feb; 20(2):441-450. PubMed ID: 31529621
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Living donor versus deceased donor liver transplantation: a surgeon-matched comparison of recipient morbidity and outcomes.
    Reichman TW; Katchman H; Tanaka T; Greig PD; McGilvray ID; Cattral MS; Renner EL; Selzner M; Ghanekar A; Levy G; Grant DR
    Transpl Int; 2013 Aug; 26(8):780-7. PubMed ID: 23746118
    [TBL] [Abstract][Full Text] [Related]  

  • 74. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
    Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
    Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.
    Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A
    Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Strength of donor-specific antibodies with the use of Luminex single-antigen beads is a reliable predictor of acute rejection in living-relative kidney recipients.
    Tang MY; Wang QH; Wang J; Gao X; Wu L; Tan JM
    Transplant Proc; 2015 Mar; 47(2):309-12. PubMed ID: 25769565
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations.
    Dieplinger G; Ditt V; Arns W; Huppertz A; Kisner T; Hellmich M; Bauerfeind U; Stippel DL
    Transpl Int; 2014 Jan; 27(1):60-8. PubMed ID: 24131087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.